1[1]Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus[J].Diabetes Care 1999,22(Suppl 1):5-22
2[2]Zimmerman BR,Diagnosis and classifications in Zimmerman BR,ed.Medical management of type 2 diabetes[M].4th ed.Alexandria,VA: American Diabetes Association; 1998:2-61
3[4]Keilson L,Mather S,Walter YH et al.Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus[J].J Clin Endocrinol Metab,2000,85:1081-1086
4[5]Hanefeld M,Bonter KP,Dikinson S,et al.Rapid and sbort-acting mealtime insulin secretion with nsteglinide controls both prandial and mean glycemia[J].Diabetes Care,2000,23:202-207
5[6]Hanif W,Kumar S.Nateqlinide: a new rapid-acting insulinotropic agent[J].Expert Opin Pharmacother,2001,2(6): 1027-1031
6[7]Kikuchi M.Modulation of insulin secretion in non-insulin-dependent diabetes mellitus by two novel oral hypoqlycaemic agents,NN623 and A4166[J].Diabe Med,1996,13:151-155
7[8]Hirschberg Y,Karara AH,Pietri AO,et al.Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin[J].Diaber Care.2000,23:349-353
8[9]Hu S,Wang S.Effect of insulinotropic agents nateglinide on KV and Ca(2+) channels in pencreatic beta-cell[J].Eur J Pharmacob.2001,427(2) :94-104
9[10]Karara AH,Dunning BE,Mcload JF.The effect of food on the oralbioavilability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects[J].J Clin Pharmacol,1999(2):39:171-179
10[11]Luzio SD,Anderson Dm,Owens DR.Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects [ J ].J Clin Endocrinol Medtab,2001,86(10) :4874-4880
